Table 1:

Values of 4 indicators for characterizing atrophya

GroupGlobal NormalizationSPM8 plus DARTELSPM2
Target VOIWhole-Brain Extent (%)Target VOIWhole-Brain Extent (%)
SeverityExtent (%)RatioSeverityExtent (%)Ratio
Healthy controls−0.7 ± 0.54.4 ± 9.80.8 ± 1.52.5 ± 4.7NANANANA
+0.7 ± 0.32.0 ± 4.91.3 ± 2.81.4 ± 0.90.5 ± 0.31.8 ± 7.30.5 ± 1.82.6± 3.1
Very mild AD−1.8 ± 0.9b39.0 ± 35.5b9.9 ± 8.9b5.4 ± 7.6bNANANANA
+2.2 ± 0.9b49.2 ± 30.2b12.9 ± 7.8b4.1 ± 2.5b1.6 ± 1.0b30.8 ± 32.1b6.7 ± 7.8b5.4 ± 3.7b
Mild AD−2.2 ± 0.7b53.7 ± 29.8b12.8 ± 8.8b5.5 ± 5.1bNANANANA
+2.7 ± 0.8b63.7 ± 25.8b15.4 ± 7.8b4.3 ± 1.9b2.1 ± 1.1b42.0 ± 32.3b9.6 ± 9.2b5.4 ± 3.0b
Moderate-to-advanced AD−2.8 ± 1.0b,c,d72.2 ± 26.5b,c,d8.4 ± 7.2b15.1 ± 14.0b,c,dNANANANA
+3.0 ± 1.0b,c68.7 ± 24.1b,c11.7 ± 6.7b,d7.1 ± 3.7b,c,d2.6 ± 1.4b,c56.3 ± 33.2b,c7.6 ± 6.2b9.0 ± 5.0b,c,d

  • Note:—NA indicates not applicable; +, presence; −, absence.

  • ↵a Tukey honest significance test in each condition of global normalization.

  • ↵b P < .001 versus healthy controls.

  • ↵c P < .001 versus very mild AD group.

  • ↵d P < .001 versus mild AD group.